Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index

AIMS: In heart failure with reduced ejection fraction (HFrEF), there is an ‘obesity paradox’, where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a sodium–glucose co‐transporter 2 inhibitor according to...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamson, Carly, Jhund, Pardeep S., Docherty, Kieran F., Bělohlávek, Jan, Chiang, Chern‐En, Diez, Mirta, Drożdż, Jarosław, Dukát, Andrej, Howlett, Jonathan, Ljungman, Charlotta E.A., Petrie, Mark C., Schou, Morten, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., Bengtsson, Olof, Langkilde, Anna Maria, Lindholm, Daniel, Sjöstrand, Mikaela, McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Focused Issue on Comorbidities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292627/
https://www.ncbi.nlm.nih.gov/pubmed/34272791
http://dx.doi.org/10.1002/ejhf.2308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292627/
https://www.ncbi.nlm.nih.gov/pubmed/34272791
http://dx.doi.org/10.1002/ejhf.2308

Ejemplares similares